Sign in

    Sophie Kanon

    Research Analyst at Evercore ISI

    Sophie Kanon is an Equity Research Analyst at Evercore ISI specializing in coverage of the medical devices sector, with a focus on companies such as Zimmer Biomet Holdings Inc. Her work emphasizes in-depth financial analysis and insights into industry trends, with early career data indicating growing responsibility in analyst roles. Kanon's performance metrics and professional credentials, including specific FINRA securities licenses and previous career history, have not yet been publicly documented but reflect her emerging analyst status within the firm. She joined Evercore ISI in the last several years, contributing to their healthcare research team with targeted questions on earnings calls and financial commentary for investors.

    Sophie Kanon's questions to ZIMMER BIOMET HOLDINGS (ZBH) leadership

    Sophie Kanon's questions to ZIMMER BIOMET HOLDINGS (ZBH) leadership • Q3 2024

    Question

    Sophie Kanon of Evercore ISI asked about expectations for gross and operating margins in 2025, including any updates on previously mentioned headwinds.

    Answer

    CFO Suketu Upadhyay confirmed that Zimmer Biomet continues to expect operating margin expansion into 2025, in line with its long-range plan of at least 30 basis points per year. He noted that while gross margin will face some FX headwinds, it is expected to be relatively stable, supported by operational progress and a better pricing environment.

    Ask Fintool Equity Research AI